Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;22(3):366-387.
doi: 10.1002/wps.21110.

Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management

Affiliations

Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management

Michael Berk et al. World Psychiatry. 2023 Oct.

Abstract

Populations with common physical diseases - such as cardiovascular diseases, cancer and neurodegenerative disorders - experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment, increased mortality, and greater health care utilization and costs. Comorbidity can also result in a range of clinical challenges, such as a more complicated therapeutic alliance, issues pertaining to adaptive health behaviors, drug-drug interactions and adverse events induced by medications used for physical and mental disorders. Potential explanations for the high prevalence of the above comorbidity involve shared genetic and biological pathways. These latter include inflammation, the gut microbiome, mitochondrial function and energy metabolism, hypothalamic-pituitary-adrenal axis dysregulation, and brain structure and function. Furthermore, MDD and physical diseases have in common several antecedents related to social factors (e.g., socioeconomic status), lifestyle variables (e.g., physical activity, diet, sleep), and stressful live events (e.g., childhood trauma). Pharmacotherapies and psychotherapies are effective treatments for comorbid MDD, and the introduction of lifestyle interventions as well as collaborative care models and digital technologies provide promising strategies for improving management. This paper aims to provide a detailed overview of the epidemiology of the comorbidity of MDD and specific physical diseases, including prevalence and bidirectional risk; of shared biological pathways potentially implicated in the pathogenesis of MDD and common physical diseases; of socio-environmental factors that serve as both shared risk and protective factors; and of management of MDD and physical diseases, including prevention and treatment. We conclude with future directions and emerging research related to optimal care of people with comorbid MDD and physical diseases.

Keywords: Depression; cancer; cardiovascular diseases; childhood trauma; collaborative care; comorbidity; digital technologies; inflammation; lifestyle factors; physical diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta‐analytic data on the risk for mortality and physical diseases among individuals with major depressive disorder compared to people without this condition. ES – effect size (risk ratio or odds ratio), BMI – body mass index (see also supplementary information).
Figure 2
Figure 2
Point prevalence of comorbid major depressive disorder (MDD) in physical diseases, using estimates from published meta‐analyses (see also supplementary information).
Figure 3
Figure 3
Association between major depressive disorder (MDD) and physical diseases according to Mendelian randomization studies. Asterisks indicate conditions where the evidence is mixed (see also supplementary information).
Figure 4
Figure 4
Environmental and biological factors influencing the comorbidity between major depressive disorder and physical diseases. HPA – hypothalamic‐pituitary‐adrenal.

Similar articles

Cited by

References

    1. Ferrari A, Somerville A, Baxter A et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013;43:471‐81. - PubMed
    1. Vaccarino V, Badimon L, Bremner JD et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41:1687‐96. - PMC - PubMed
    1. Wu Q‐E, Zhou A‐M, Han YP et al. Poststroke depression and risk of recurrent stroke: a meta‐analysis of prospective studies. Medicine 2019;98:e17235. - PMC - PubMed
    1. Krebber A, Buffart L, Kleijn G et al. Prevalence of depression in cancer patients: a meta‐analysis of diagnostic interviews and self‐report instruments. Psychooncology 2014;23:121‐30. - PMC - PubMed
    1. Scott AJ, Sharpe L, Hunt C et al. Anxiety and depressive disorders in people with epilepsy: a meta‐analysis. Epilepsia 2017;58:973‐82. - PubMed